

Renal Phosphate Wasting in Fibrous Dysplasia of Bone Is Part of a Generalized Renal Tubular Dysfunction Similar to That Seen in Tumor-Induced Osteomalacia

MICHAEL T. COLLINS,¹ CAROLINE CHEBLI,² JANET JONES,³ HARVEY KUSHNER,⁴
MARK CONSUGAR,⁵ PIERO RINALDO,⁵ SHLOMO WIENTROUB,⁶ PAOLO BIANCO,⁷ and
PAMELA GEHRON ROBEY¹

ABSTRACT

Fibrous dysplasia (FD) of bone is characterized by focal replacement of normal bone and marrow with abnormal bone and fibrous tissue. It arises from postzygotic activating mutations of the *GNAS1* gene. Hypophosphatemia due to renal phosphate wasting has been reported in association with FD as a part of the McCune-Albright Syndrome (MAS), which is characterized by FD, skin hyperpigmentation, and precocious puberty. To date, the prevalence and mechanism of phosphate wasting has not been well studied. We evaluated 42 patients with FD/MAS. Serum and urine samples were tested for indices of mineral metabolism, amino acid handling, and markers of bone metabolism. Twenty (48%) patients had some degree of renal phosphate wasting. Nephrogenous cyclic adenosine monophosphate (cAMP) was normal in FD patients, suggesting that the underlying cause of phosphate wasting is not the presence of activating *GNAS1* mutations in the kidney. In addition, there was evidence of a more generalized renal tubulopathy as represented by the presence of abnormal vitamin D metabolism, proteinuria in 36 (86%) patients, and aminoaciduria in 39 (94%) patients. Renal phosphate wasting significantly correlated with the degree of bone involvement, as assessed by serum and urine markers of bone metabolism, suggesting that a circulating factor produced by FD bone and impacting on the kidney may be the mechanism. These data show that phosphaturia as part of a generalized renal tubulopathy represents the most common extraskeletal manifestation of FD and that the observed tubulopathy is similar to that seen in tumor-induced osteomalacia (TIO). (*J Bone Miner Res* 2001;16:806–813)

Key words: fibrous dysplasia, phosphaturia, tumor-induced osteomalacia, phosphatonin, McCune-Albright syndrome

¹Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA.

²Department of Orthopedic Surgery, Westchester Medical Center, Valhalla, New York, USA.

³Arthritis Research Branch, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.

⁴Biomedical Computer Research Institute, Philadelphia, Pennsylvania, USA.

⁵Biochemical Genetics Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic Foundation, Rochester, Minnesota, USA.

⁶Department of Pediatric Orthopedic Surgery, Dana Children's Hospital, Tel-Aviv Medical Center, Tel-Aviv, Israel.

⁷Division of Pathology, Department of Experimental Medicine, University of Rome 'La Sapienza,' Rome, Italy.

INTRODUCTION

FIBROUS DYSPLASIA (FD) of bone is characterized by replacement of normal bone and bone marrow by a benign fibroosseous tissue.^(1,2) It may exist at a single skeletal site (monostotic fibrous dysplasia [MFD]), at multiple skeletal sites (polyostotic fibrous dysplasia [PFD]), or as part of the McCune-Albright syndrome (MAS). MAS is a rare disease classically characterized by the triad of PFD, café-au-lait pigmentation of the skin, and precocious puberty (PP).^(3,4) The molecular basis of the disease is a postzygotic activating mutation of the GNAS1 gene, which codes for the G protein, Gs α .^(5,6) Gs α is a key regulator of the cyclic adenosine monophosphate (cAMP) signaling cascade, and certain mutations of this protein (G227L, R201C, R201H, R201S, and R201G) cause persistent activation of adenylyl cyclase and increased production of intracellular cAMP.⁽⁷⁾ It has been postulated that germ line mutations are lethal.⁽⁸⁾ The postzygotic occurrence of the mutations results in somatic mosaicism, with patients presenting with a broad spectrum of affected tissues. If the mutation occurs early in development, multiple tissues are involved, and the complete syndrome, MAS, results. Limited tissue involvement may result if the mutation occurs later in development. This may be the case in isolated pituitary adenomas that harbor GNAS1 mutations.⁽⁹⁾ If the mutation occurs only in skeletal tissues, the result is MFD or PFD.

Rickets and/or osteomalacia have been reported anecdotally as a rare complication of MAS, with approximately 12 cases in the literature.^(10–17) One case of osteomalacia has been reported in association with isolated FD.⁽¹³⁾ The rickets/osteomalacia in FD has been shown to be associated with hypophosphatemia and renal phosphate wasting.^(12,14,18) It has been suggested that renal phosphate wasting in FD/MAS may be caused by either renal tubule cells bearing Gs α mutations⁽¹⁹⁾ or, alternatively, to the presence of a circulating phosphaturic factor produced by the dysplastic bone.⁽²⁰⁾ However, there is little evidence to support either possibility to date.

In an effort to establish the prevalence and etiology of phosphate wasting in FD/MAS, we performed an evaluation of mineral metabolism in 42 consecutive patients with FD/MAS. Because phosphaturia often coexists with additional abnormalities in renal function in other diseases such as tumor-induced osteomalacia (TIO), X-linked hypophosphatemia, and the Fanconi's syndrome,^(21–24) we also investigated other aspects of renal tubular function including vitamin D metabolism and urinary protein and amino acids.

MATERIALS AND METHODS

FD/MAS patients

Forty-two patients who were enrolled in an Institutional Review Board (IRB)-approved study (98-D-0145) of the natural history of FD/MAS at the National Institute of Dental and Craniofacial Research of the National Institutes of Health were studied. The diagnosis of FD was confirmed by some combination of clinical history, radiographic findings, histopathological findings, and, when needed, se-

quence analysis of the appropriate region of the GNAS1 gene.^(1,25) Only patients in whom the diagnosis was clearly established were included in the analysis.

All patients were maintained on a hospital diet. The average daily intake of the following nutrients were as follows: calcium, 850 mg (range, 690–1066 mg); phosphorus, 1312 mg (range, 1065–1744 mg); potassium, 3596 mg (range, 3107–4595 mg); sodium, 5111 mg (range, 4282–6412 mg).

At the time of evaluation, four of the patients in this series were children (<18 years old), yet had PP, which leads to advanced bone age, and were skeletally mature. In statistical analyses these four patients were analyzed according to their bone age, as assessed by the method of Gruelich and Pyle,⁽²⁶⁾ rather than chronological age.

Hyperparathyroid patients

Nephrogenous cAMP was measured in a randomly selected group of 10 patients with primary hyperparathyroidism (PHPTH) and were seen under a different IRB-approved protocol for the treatment of PHPTH (91-DK-0085).

Serum and urinary measures

All measurements of compounds in sera were performed in duplicate on specimens collected on successive days at 8 a.m. after an overnight fast while on a hospital diet. Urine measurements were performed on aliquots taken from 24-h collections, which were collected coincident with the serum samples and had been refrigerated throughout the collection. Measurements of serum and urinary creatinine, calcium, phosphorus, protein, amino acids, parathyroid hormone (PTH), vitamin D metabolites, and others were all assessed by standard commercially available techniques.

Renal phosphate handling was assessed by calculating the maximum rate of reabsorption of phosphate relative to the glomerular filtration rate (TmP/GFR) from 24-h urine collections, an adaptation of the technique and nomogram of Bijovet.⁽²⁷⁾ Age- and gender-appropriate norms for TmP/GFR were taken from the literature.⁽²⁸⁾ Vitamin D₃ metabolites, 25-hydroxyvitamin D₂ [25(OH)₂] and 1,25-dihydroxyvitamin D₃ [1,25(OH)₂D₃], were assayed using commercially available high-pressure liquid chromatography (HPLC) and radioreceptor assays, both with a percent CV (%CV) of 12% (Mayo Medical Laboratories, Rochester, MN, USA). The N-terminal segment of bone collagen (N-telopeptide) was measured using a commercially available ELISA with a %CV of 10% (Mayo Medical Laboratories, Rochester, MN, USA). Collagen cross-linking elements (pyridinoline [PYD] and deoxypyridinoline [DPYD]) were measured by commercially available assays using an HPLC technique with a %CV of 4.7% (Mayo Medical Laboratories). Bone-specific alkaline phosphatase was measured using a commercially available ELISA with a %CV of 4.2–8.7% (Endocrine Science, Calabasas Hills, CA, USA). Quantitative amino acids analyses were performed using a Beckman 6300 amino acid analyzer (Beckman, Palo Alto, CA, USA) equipped with a lithium 10-cm column according to an established method.⁽²⁹⁾ Nephrogenous cAMP was

TABLE 1. PATIENT DEMOGRAPHICS

| | Children ^a | Adults | Total |
|---|-----------------------|--------|-------|
| Male | | | |
| age range: 5–51 years | 10 | 7 | 17 |
| mean: 20.8 ± 14.5 years | | | |
| Female | | | |
| age range: 7–57 years | 9 | 16 | 25 |
| mean: 24.6 ± 13.3 years | | | |
| Total | 19 | 23 | 42 |
| Diagnosis | | | |
| PFD | 2 | 7 | 9 |
| FD and café-au-lait or FD and endocrinopathy | 5 | 4 | 9 |
| MAS | 12 | 12 | 24 |
| Total | 19 | 23 | 42 |

^a Chronological age < 18 years.

assayed with a commercially available HPLC technique with a %CV of <10% (Mayo Medical Laboratories).

Statistical analysis

Bivariate correlations among numerically continuous variables were computed using the Pearson or Spearman r , and simple linear regression lines were plotted. Correlations also were computed controlling for (partialing out) age. Two-way analysis of variance (ANOVA) was performed to compare means between gender and age groups with a test for interaction. Values of $p \leq 0.05$ were considered statistically significant. No Bonferroni adjustments were performed. All analyses were performed using SAS version 6.12 (SAS Institute, Inc., Cary, NC, USA).

RESULTS

Patient demographics

Patient demographics are presented in Table 1. The patients studied had a spectrum of bone disease that ranged from mild MFD to severe PFD (with nearly every bone involved, panostotic). Ages ranged from 5 to 57 years. There were 25 female and 17 male patients—36 whites, 2 blacks, 3 Hispanics, and 1 Asian.

Renal phosphate wasting

Given the age- and gender-specific differences in TmP/GFR,⁽²⁸⁾ the results of TmP/GFR testing are grouped and displayed accordingly (Fig. 1). The normal ranges are derived from the literature⁽²⁸⁾ with the normal ranges (mean ± 2 SD) indicated. Twenty patients (48%) had a reduced TmP/GFR and thus some degree of phosphate wasting. The correlation between TmP/GFR and serum phosphorus was strong ($r = 0.79$ for children and $r = 0.89$ for adults, data not shown). However, in 13 of the 20 patients with a low TmP/GFR (65%), the serum phosphorus was within the age-specific normal range (data not shown). Using a two-




FIG. 1. TmP of phosphate per GFR (TmP/GFR) in patients with FD. Individual patient values of TmP/GFR are indicated and grouped according to age as indicated. The normal range (derived from the literature,⁽²⁷⁾ mean ± 2 SD) for each age and gender group is indicated by the box. Twenty (42%) of the patients had a TmP/GFR below normal.

way ANOVA for TmP/GFR, there was a statistically significant interaction between gender and TmP/GFR in the 26- to 45-year age group; all of the males in this group had a low TmP/GFR and 8 of the 9 females had a TmP/GFR within the normal range.

Vitamin D metabolism

In normal subjects, serum phosphorus is an important regulator of the $1,25(\text{OH})_2\text{D}_3$ concentration, and an inverse relationship exists between the two variables⁽³⁰⁾; that is, lower serum phosphate concentrations are associated with higher $1,25(\text{OH})_2\text{D}_3$ concentrations. In our population, the opposite was observed. There was a statistically significant positive correlation between serum phosphorus and $1,25(\text{OH})_2\text{D}_3$ levels (Fig. 2). Of the 42 patients, 2 patients (5%) had undetectable serum $1,25(\text{OH})_2\text{D}_3$ levels (<5 pg/ml) on repeated measurement.

Proteinuria and aminoaciduria

Because proteinuria and aminoaciduria have been associated with other renal tubulopathies such as TIO and the Fanconi syndrome,^(21,24) we performed assays to determine if they also occur in patients with FD. Thirty-seven patients (86%) showed some degree of proteinuria (Fig. 3). The highest urinary protein observed was 291 mg/24 h, reflecting a relatively mild degree of proteinuria. The electrophoretic pattern revealed a low molecular weight distribution, consistent with a tubular proteinuria (data not shown). Although the concentrations of serum amino acids were in the normal range, 39 patients (94%) showed some degree of aminoaciduria. Only 3 patients (7%) had a normal urinary amino acid screen (Table 2). Table 3 is a representative profile of urinary amino acids of 1 patient with aminoaciduria. This shows the finding of a generalized aminoaciduria,




FIG. 2. Relationship between serum 1,25(OH)₂D₃ and serum phosphorus. The average of two measurements of serum phosphorus are plotted against the average of two determinations of serum 1,25(OH)₂D₃ for each patient. Unlike that which is seen under normal physiological conditions, a positive correlation exists between the serum phosphorus concentration and the serum 1,25(OH)₂D₃ values. The normal range is indicated by the area between the hatched lines.




FIG. 3. Urine protein per 24 h in patients with FD. The average of two 24-h urine collections is represented by a point for each patient. The normal range is indicated by the box. Thirty-six patients (86%) had some degree of proteinuria.

not suggestive of defects in specific amino acid transport systems.

In addition to the finding of aminoaciduria, chromatography of urinary amino acids in patients with FD showed a distinct pattern, different from that of a normal control subject (Fig. 4). Unknown compounds were consistently detected in the urine of affected FD patients who displayed aminoaciduria (peaks labeled with asterisks in Fig. 4). To exclude the possibility that the aberrant peaks simply represented an elevated concentration of physiological amino acids with a similar or overlapping retention time, samples

TABLE 2. AMINOACIDURIA IN PATIENTS WITH FD

| Number of amino acids/28 elevated in urine | Number of subjects with abnormality (%) |
|--|---|
| 0 | 3 (7) |
| 1-5 | 15 (36) |
| 6-10 | 11 (24) |
| 11-15 | 7 (17) |
| ≥16 | 7 (17) |

were reanalyzed using a different HPLC-based method in which the elution profile for the amino acids is different. These additional analyses confirmed that the unusual peaks were not physiological amino acids. Further characterization of the modified amino acids represented by these peaks is ongoing.

Nephrogenous cAMP

It has been suggested that renal phosphate wasting sporadically observed in MAS patients may be the result of the presence of Gsα mutations in renal tubular cells, and that the presence of mutation in the kidney would result in an elevation of nephrogenous cAMP, as in hyperparathyroidism.⁽¹⁹⁾ The mean (±SD) basal nephrogenous cAMP in the FD patients was in the normal range and significantly less than a group of PHPTH patients (*p* < 0.05; Fig. 5).

Correlation between bone disease activity and TmP/GFR

By analogy to TIO, the renal phosphate wasting in FD also may be caused by secretion of a circulating factor.⁽²⁰⁾ If so, we hypothesize that markers of bone metabolism, used here as an indicator of bone disease activity, would be correlated negatively with TmP/GFR. The range, mean, and SD of various markers of bone metabolism (alkaline phosphatase, bone-specific alkaline phosphatase, osteocalcin, N-telopeptide, and PYD and DPYD cross-links), as well the correlation of the markers to TmP/GFR, are presented in Table 4. To control for the fact that markers of bone metabolism in children are normally elevated relative to adults, the correlations between bone markers and TmP/GFR were calculated controlling for (partialing out) age (Table 4). Once age is adjusted for, there is a statistically significant negative correlation between the markers of bone metabolism to TmP/GFR (*r* = -0.366 to -0.640; *p* = 0.02 to <0.001). Thus, the higher level of bone activity, the lower the TmP/GFR and the greater the degree of renal phosphate wasting.

Significant negative findings

In this series of patients, there was no evidence of mag- nesuria, or calciuria as is seen in PHPTH. Serum bicarbonate and urinary pH were normal in all patients. Except for one 57-year-old patient with type 2 diabetes mellitus, there was no evidence of glucosuria. Therefore, many of the

TABLE 3. URINARY AMINO ACIDS IN A PATIENT WITH FD

| Amino acid | Value ^a | Normal | Amino acid | Value ^a | Normal |
|-----------------------------|--------------------|-----------|----------------------------|--------------------|----------|
| Taurine | 1002 ^b | (35–260) | Arginine | 32 ^b | (10–25) |
| Threonine | 585 ^b | (25–100) | Carnosine | 115 | (34–220) |
| Serine | 1185 ^b | (93–210) | 3-Methylhistidine | 313 ^b | (42–135) |
| Asparagine | 715 ^b | (15–40) | Histidine | 2981 ^b | (46–725) |
| Glutamic acid | 14 | (13–22) | Methionine | 110 ^b | (7–20) |
| Glutamine | 1257 ^b | (15–400) | Lysine | 700 ^b | (19–140) |
| Glycine | 6021 ^b | (195–855) | Ornithine | 24 ^b | (3–16) |
| Alanine | 1106 ^b | (65–190) | β -Aminobutyric acid | 53 | (25–96) |
| Citrulline | <5 | (0–13) | β -Alanine | 21 | (0–42) |
| α -Aminodipic acid | 179 ^b | (25–78) | Cystathionine | 24 ^b | (2–7) |
| Valine | 82 ^b | (17–37) | Phenylalanine | 114 ^b | (20–61) |
| Cystine | 78 ^b | (11–53) | Tyrosine | 387 ^b | (30–83) |
| Leucine | 82 ^b | (9–23) | Isoleucine | 77 ^b | (3–15) |
| α -Aminobutyric acid | 39 ^b | (7–25) | 1-Methyldistidine | 1709 ^b | (41–300) |

^a Units = $\mu\text{mol}/24\text{ h}$.

^b Beyond normal range.




FIG. 4. Chromatographic profile of urinary amino acids in a patient with FD and in a normal control. The top panel is a normal control subject and the bottom panel is a patient with FD. The legend for numbered peaks is as follows: (1) taurine, (2) urea, (3) glucosaminic acid (internal standard), (4) hydroxyproline, (5) threonine, (6) serine, (7) glutamine, (8) glycine, (9) alanine, (10) valine, (11) cysteine, (12) methionine, (13) cystathionine, (14) isoleucine and leucine, (15) ammonia, (16) aminoethylcysteine (internal standard), (17) 1-methylhistidine, (18) histidine, and (19) 3-methylhistidine. Peaks highlighted and marked with an asterisk correspond to abnormal peaks consistently detected in the urine of FD patients. The possibility that these represent an elevation in normal physiological amino acids was excluded and their identity currently is unknown.

components of a generalized renal tubulopathy that are seen in cases of renal tubular damage, such as an acquired Fanconi syndrome, were absent. Furthermore, there was no evidence of cumulative or progressive renal damage, as indicated by the lack of change in GFR, or association between GFR and age.

DISCUSSION

Before this study, the prevalence of either hypophosphatemia and/or renal phosphate wasting in association with FD had not been examined closely. In a large series of patients with FD, we have established that renal phosphate wasting is a common finding in FD. Twenty of the 42 patients (48%) in our series show some degree of phosphate

wasting. Of note is the fact that the serum phosphorus concentration of 13/20 (65%) patients with a low TmP/GFR was in the normal range, indicating that calculation of the TmP/GFR is necessary to establish phosphate wasting. We also found that the renal phosphate wasting is part of a more general proximal renal tubulopathy as manifested by altered vitamin D metabolism, proteinuria, and aminoaciduria. This is the first report indicating that a proximal renal tubulopathy is a common feature in patients with FD.

Renal phosphate wasting—endogenous Gs α mutation or phosphaturic factor?

The etiology of the phosphate wasting observed in association with FD is debated. Because Gs α mutations have been found in kidney tissue in severe, neonatal lethal MAS cases,⁽⁵⁾ it has been suggested that the abnormality is en-




FIG. 5. Comparison of nephrogenous cAMP between patients with PHPTH and FD. The average and SD of nephrogenous cAMP in patients with PHPTH ($n = 10$) and patients with FD ($n = 42$) are shown. The normal range of nephrogenous cAMP is indicated. The groups are statistically different from each other (one-way ANOVA; $p < 0.05$).

ogenous to renal tubular cells.⁽¹⁹⁾ Others speculate that it is the effect of a phosphaturic factor produced by FD bone.⁽²⁰⁾ In an effort to distinguish between these two pathogenetic mechanisms, we performed an extensive clinical and biochemical evaluation of a series of patients with FD.

PTH activation of renal tubular $Gs\alpha$ generates an elevation in nephrogenous cAMP,⁽³¹⁾ which is a common finding in hyperparathyroidism.⁽³²⁾ Therefore, if $Gs\alpha$ was constitutively activated in the kidney because of the presence of activating mutations, it would be expected that FD patients with phosphate wasting also would have elevated basal nephrogenous cAMP levels. This was not observed in our study. The basal levels of nephrogenous cAMP were in the normal range in all patients and significantly lower than those in a group of patients with PHPTH. Our findings of decreased Tmp/GFR in conjunction with normal basal nephrogenous cAMP suggest that a mechanism other than endogenous renal $Gs\alpha$ mutations is the cause of phosphate wasting, although it cannot be ruled out that some patients also may have activating mutations in renal $Gs\alpha$.

Further distinguishing these findings from those seen in PHPTH is the relationship between serum phosphorus and $1,25(OH)_2D_3$ levels. Serum phosphorus is a key regulator of $25(OH)D_3$ - 1α -hydroxylase (1α -hydroxylase) activity in the renal proximal tubule, and thus serum levels of $1,25(OH)_2D_3$. Under normal physiological conditions, low serum phosphorus stimulates 1α -hydroxylase activity and increases the serum level of $1,25(OH)_2D_3$.⁽³⁰⁾ In PHPTH, $1,25(OH)_2D_3$ levels are normal or high and maintain an inverse relationship (negative correlation) to serum phosphorus.⁽³⁰⁾ We found that in FD lower serum phosphate was correlated with lower serum $1,25(OH)_2D_3$. This suggests that there is an alteration of 1α -hydroxylase activity in FD. A similar observation has been made in TIO and X-linked hypophosphatemia but not in the phosphaturia of hyperparathyroidism.

Supporting the hypothesis that fibrous dysplastic bone elaborates a phosphaturic factor, is the report of a patient with FD and phosphate wasting in whom the phosphate wasting corrected after extensive resection of FD tissue.⁽¹³⁾ The fact that markers of bone metabolism, as a surrogate marker for FD tissue burden, significantly correlate with Tmp/GFR (Table 4) also supports the hypothesis that the etiology of the phosphate wasting is a phosphaturic factor elaborated by FD bone.

Based on characterization of patients with TIO, current thinking suggests that the abnormal phosphate metabolism is mediated by a systemic factor "phosphatonin" and that abnormalities in its metabolism result in the generation of systemic osteomalacia.⁽²²⁾ This putative phosphate-regulating factor has not yet been isolated, and it is not known what cell type produces it, although bone-forming cells are likely candidates.⁽³³⁾ Mutated cells within FD lesions may produce abnormal levels of this factor; alternatively, they may deregulate its production by normal osteogenic cells or cells elsewhere in the body. Another possibility is that the hypermetabolic fibrous dysplastic bone produces a factor(s) toxic to the kidney.

Even more prevalent than phosphate wasting and derangement of vitamin D metabolism is the finding of proteinuria and aminoaciduria in most of the patients in this series. Proteinuria and aminoaciduria also are seen in TIO.⁽²¹⁾ The magnitude of the proteinuria was mild (the highest value was 291 mg/24 h) and characterized by the presence of low molecular weight proteins in the urine. Relative to the glomerulonephropathies, in which grams of protein per day can be detected in the urine, the proteinuria in FD is not likely to be of major clinical significance. The aminoaciduria was variable with respect to the number of amino acids in which the concentration was elevated in the urine. The pattern was that of a generalized aminoaciduria, indicating that it was not an isolated transport system that was affected. Interestingly, the aminoaciduria was further characterized by the consistent presence of unknown metabolites in the urine of patients with FD (Fig. 4).

The etiology of the aminoaciduria is not clear. Some have suggested that high PTH and/or low serum vitamin D can directly impact the renal tubule and cause aminoaciduria.⁽³⁴⁾ Although hyperparathyroidism can be associated with aminoaciduria, this is an uncommon finding and in those cases in which it is present, it usually is an isolated glycinuria.⁽³⁴⁾ It is not likely that changes in vitamin D metabolism or hyperparathyroidism account for the common place occurrence of aminoaciduria seen in our patients. Although 7 patients (17%) had serum vitamin D levels low enough to induce secondary hyperparathyroidism at the initial evaluation (data not shown), the secondary hyperparathyroidism resolved with vitamin D replacement. The data shown in this study represent evaluations done at least 3 months after vitamin D replacement and normalization of serum PTH. Furthermore, only 2 (5%) of the patients had persistent abnormalities in vitamin D levels [decreased serum $1,25(OH)_2D_3$] at the time of testing; yet 40 (94%) of the patients had some degree of aminoaciduria.

The renal findings in FD patients are similar to those observed in patients with TIO, X-linked hypophosphatemia,

TABLE 4. MARKERS OF BONE METABOLISM IN FD AND CORRELATION WITH TmP

| Marker | Average | SD | Range | Normal range ^a |
|--|----------------|-------|-----------|---------------------------|
| Alkaline phosphatase (U/liter) | 541 | 701 | 61–4115 | 37–116 |
| Bone-specific alkaline phosphatase (ng/ml) | 178.7 (n = 34) | 283.4 | 10–1406 | <2–24 |
| Osteocalcin (μ g/liter) | 155.8 | 149.8 | 7–699 | 2–15 |
| N-telopeptide (pmol/ μ mol Cr) | 720.7 | 917.7 | 48–4665 | 0–64 |
| PYD (nmol/mmol Cr) | 383.7 (n = 40) | 437.3 | 30.9–1889 | 18–40 |
| DPYD (μ mol/mol Cr) | 101.7 | 124.5 | 47–421 | 5–14 |

| Marker | Spearman rho | p Value | Partial Spearman rho ^b | p Value |
|--|-----------------|---------|-----------------------------------|---------|
| Alkaline phosphatase (U/liter) | –0.365 | 0.02 | –0.393 | 0.01 |
| Bone-specific alkaline phosphatase (ng/ml) | –0.203 (n = 34) | 0.25 | –0.463 (n = 34) | 0.008 |
| Osteocalcin (μ g/liter) | –0.298 | 0.06 | –0.422 | 0.007 |
| N-telopeptide (pmol/ μ mol Cr) | –0.189 | 0.23 | –0.366 | 0.02 |
| PYD (nmol/mmol Cr) | –0.279 (n = 40) | 0.08 | –0.640 (n = 40) | <0.001 |
| DPYD (μ mol/mol Cr) | –0.340 | 0.03 | –0.397 | 0.01 |

n = 42 unless otherwise indicated.

^a adult normal range

^b controlled for (partialing out) age

autosomal dominant hypophosphatemia, and the Fanconi syndrome. In these conditions the renal findings are phosphate wasting, mild proteinuria, aminoaciduria, and normal nephrogenous cAMP.^(21,24,35,36) The absence of carbonaturia, glucosuria, and acidosis in FD distinguishes it from the Fanconi syndrome. Thus, it appears that the phosphate wasting observed in association with FD is more similar to that seen in the phosphotonin-mediated phosphate wasting syndromes, TIO, and X-linked and autosomal dominant hypophosphatemia and distinct from that seen in either PHPH or the tubular damage (Fanconi) syndromes.

Clinical significance

Given the recent report that FD lesions can be osteomalacic,⁽²⁵⁾ the finding of renal phosphate wasting is of clinical significance. Renal phosphate wasting with chronically low serum phosphorus (or perhaps even low to normal levels in growing children) may influence the development of lesional osteomalacia. Undermineralization of FD bone may contribute to the development of the shepherd's crook deformity of the proximal femur, the quality of fracture healing, and to the rare but serious complication of platybasia of the skull. Therefore, it is critical to assess the phosphate status of patients with FD. We currently prescribe phosphorus supplementation for patients both with low serum phosphorus and with low-normal serum phosphorus but a low TmP/GFR. As in other patients with phosphate wasting syndromes, phosphate supplementation usually results in secondary hyperparathyroidism, the prevention of which is brought about by adding vitamin D (calcitriol) to the regimen. Long-term studies in FD patients are required to determine if raising serum phosphorus levels will improve the quality and mechanical properties of osteomalacic bone

in FD. Furthermore, it is clinically relevant to determine the presence or absence of phosphate wasting before treatment with bisphosphonates, which have been reported to be beneficial in the treatment of FD, but in certain circumstances, may themselves be associated with mineralization defects.⁽³⁷⁾

Our data show that a renal tubulopathy manifested by phosphate wasting, altered vitamin D metabolism, low molecular weight proteinuria, and aminoaciduria is common in FD/MAS. In fact, the renal tubulopathy represents the most common metabolic feature in this group of patients. Our findings suggest that the cause may be a circulating factor produced by fibrous dysplastic bone, although the presence of mutations in renal Gs α cannot be excluded and may contribute. Further study is needed to determine the precise pathogenetic mechanisms and appropriate clinical care.

ACKNOWLEDGMENTS

The authors thank Stephan Marx, Jeffrey Baron, and Monica Skarulis for their generous and expert advice. We also are indebted to the Interinstitute Endocrine Training Program Fellows and the 8 West and 9 West nursing staff for their meticulous care of the patients. P.B. was supported by a Telethon Foundation ONLUS grant (E1029).

REFERENCES

1. Riminucci M, Fisher LW, Shenker A, Spiegel AM, Bianco P, Gehron Robey P 1997 Fibrous dysplasia of bone in the McCune-Albright syndrome: Abnormalities in bone formation. *Am J Pathol* **151**:1587–1600.

2. Dorfman HD, Czerniak B 1998 Fibrous Lesions. In: Czerniak B, Dorfman HD (eds.) *Bone Tumors*. Mosby, St. Louis, MO, USA, pp. 441–491.
3. Albright F, Butler A, Hampton A, Smith P 1937 Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation, and endocrine dysfunction, with precocious puberty in females: Report of 5 cases. *N Engl J Med* **216**:727–746.
4. Ringel MD, Schwindinger WF, Levine MA 1996 Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. *Medicine (Baltimore)* **75**:171–184.
5. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM 1991 Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. *N Engl J Med* **325**:1688–1695.
6. Schwindinger WF, Francomano CA, Levine MA 1992 Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. *Proc Natl Acad Sci USA* **89**:5152–5156.
7. Spiegel AM 1997 Inborn errors of signal transduction: Mutations in G proteins and G protein-coupled receptors as a cause of disease. *J Inher Metab Dis* **20**:113–121.
8. Happle R 1986 The McCune-Albright syndrome: A lethal gene surviving by mosaicism. *Clin Genet* **29**:321–324.
9. Spada A, Vallar L 1992 G-protein oncogenes in acromegaly. *Horm Res* **38**:90–93.
10. Halvorsen S, Aas K 1961 Renal tubular defects in fibrous dysplasia of bones: Report of two cases. *Acta Paediatr Scand* **50**:297–303.
11. Ryan WG, Nibbe AF, Schwartz TB, Ray RD 1968 Fibrous dysplasia of bone with vitamin D resistant rickets: A case study. *Metabolism* **17**:988–998.
12. Grubbauer HM, Stogmann W, Messner H 1974 Studies of calcium phosphate metabolism in a case of McCune-Albright syndrome with phosphate diabetes (author's translation). *Z Kinderheilkd* **117**:47–61.
13. Dent CE, Gertner JM 1976 Hypophosphataemic osteomalacia in fibrous dysplasia. *QJM* **45**:411–420.
14. Tanaka T, Suwa S 1977 A case of McCune-Albright syndrome with hyperthyroidism and vitam D-resistant rickets. *Helv Paediatr Acta* **32**:263–273.
15. McArthur RG, Hayles AB, Lambert PW 1979 Albright's syndrome with rickets. *Mayo Clin Proc* **54**:313–320.
16. Lever EG, Pettingale KW 1983 Albright's syndrome associated with a soft-tissue myxoma and hypophosphataemic osteomalacia. Report of a case and review of the literature. *J Bone Joint Surg Br* **65**:621–626.
17. Dachille RD, Goldberg JS, Wexler ID, Shons AR 1990 Fibrous dysplasia-induced hypocalcemia/rickets. *J Oral Maxillofac Surg* **48**:1319–1322.
18. Lee SH, Sanderson J 1989 Hypophosphataemic rickets and melorheostosis. *Clin Radiol* **40**:209–211.
19. Zung A, Chalew SA, Schwindinger WF, Levine MA, Phillip M, Jara A, Counts DR, Kowarski AA 1995 Urinary cyclic adenosine 3',5'-monophosphate response in McCune-Albright syndrome: Clinical evidence for altered renal adenylate cyclase activity. *J Clin Endocrinol Metab* **80**:3576–3581.
20. Whyte M 1996 Hypophosphatemic bone disease in McCune-Albright syndrome. *Calcif Tissue Int* **59**:224.
21. Drezner MK, Feinglos MN 1977 Osteomalacia due to 1alpha,25-dihydroxycholecalciferol deficiency. Association with a giant cell tumor of bone. *J Clin Invest* **60**:1046–1053.
22. Kumar R 1997 Phosphatonin—a new phosphatoretic hormone? (Lessons from tumour-induced osteomalacia and X-linked hypophosphataemia.) *Nephrol Dial Transplant* **12**:11–13 (editorial).
23. Drezner MK 1984 The role of abnormal vitamin D metabolism in X-linked hypophosphatemic rickets and osteomalacia. *Adv Exp Med Biol* **178**:399–404.
24. Brewer E 1985 The Fanconi syndrome: Clinical disorders. In: Buckalew VM, Gonick HC (eds.) *Renal Tubular Disorders*. Marcel Dekker, New York, NY, USA, pp. 475–544.
25. Bianco P, Riminucci M, Majolagbe A, Kuznetsov SA, Collins MT, Mankani MH, Corsi A, Bone HG, Wientroub S, Spiegel AM, Fisher LW, Robey PG 2000 Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. *J Bone Miner Res* **15**:120–128.
26. Pyle SI, Waterhouse AM, Greulich WW 1971 Attributes of the radiographic standard of reference for the National Health Examination Survey. *Am J Phys Anthropol* **35**:331–337.
27. Walton RJ, Bijvoet OL 1977 A simple slide-rule method for the assessment of renal tubular reabsorption of phosphate in man. *Clin Chim Acta* **81**:273–276.
28. Payne RB 1998 Renal tubular reabsorption of phosphate (TmP/GFR): Indications and interpretation. *Ann Clin Biochem* **35**:201–206.
29. Slocum RH, Cummings JG 1991 Amino acid analysis of physiological samples. In: Hommes FA (ed.) *Techniques in Diagnostic Human Biochemical Genetics*, Wiley-Liss, New York, NY, USA, pp. 87–126.
30. Gray RW, Wilz DR, Caldas AE, Lemann J Jr 1977 The importance of phosphate in regulating plasma 1,25-(OH)₂-vitamin D levels in humans: Studies in healthy subjects in calcium-stone formers and in patients with primary hyperparathyroidism. *J Clin Endocrinol Metab* **45**:299–306.
31. Juppner HBE, Kronenberg HM 1999 Parathyroid hormone. In: Favus MJ (ed.) *Primer on the Metabolic Bone Diseases*. Lippincott Williams & Wilkins, Philadelphia, PA, USA, pp. 80–87.
32. Broadus AE 1979 Nephrogenous cyclic AMP as a parathyroid function test. *Nephron* **23**:136–141.
33. Drezner MK 2000 PHEX gene and hypophosphatemia. *Kidney Int* **57**:9–18.
34. Phillips ME 1980 Aminoaciduria—its relationship to vitamin D and parathyroid hormone. *Crit Rev Clin Lab Sci* **12**:215–239.
35. Rasmussen H, Anast C 1983 Familial hypophosphatemic rickets and vitamin D-dependent rickets. In: Stanbury JB, Wynngaarden JB, Fredrickson DS, Goldstein JL, Brown MS (eds.) *The Metabolic Basis of Inherited Diseases*. McGraw-Hill, New York, NY, USA, pp. 1743–1773.
36. Econs MJ, McEnery PT, Lennon F, Speer MC 1997 Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. *J Clin Invest* **100**:2653–2657.
37. Chapurlat RD, Delmas PD, Liens D, Meunier PJ 1997 Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. *J Bone Miner Res* **12**:1746–1752.

Address reprint requests to:

Michael T. Collins

Craniofacial and Skeletal Diseases Branch

National Institute of Dental and Craniofacial Research

National Institutes of Health

Building 30, Room 228

MSC 4320

Bethesda, MD 20892-4320, USA

Received in original form August 16, 2000; in revised form November 16, 2000; accepted December 6, 2000.